Nilotinib associated with case of scurvy

Nioltinib associated with case of scurvy

(HealthDay)—Nilotinib is associated with scurvy, possibly because of its effects on cutaneous metabolism, according to a letter to the editor published online April 28 in the Journal of Cutaneous Pathology.

Allen S.W. Oak, from the University of Alabama at Birmingham, and colleagues describe a patient on nilotinib who developed a keratosis pilaris-like eruption and was subsequently diagnosed with scurvy.

The 66-year-old male was taking nilotinib for Philadelphia chromosome-positive chronic myelogenous leukemia. Seven months after beginning treatment, the patient developed keratotic papules with perifollicular erythema on the chest and abdomen, pruritic at times. No systemic symptoms were reported. A skin biopsy showed chronic perifolliculitis with hemorrhage, consistent with vitamin C deficiency. His vitamin C level was low (<0.12 mg/dL). There was improvement in the eruption at follow-up after ascorbic acid supplementation and a diet with added fresh citrus fruits and vegetables.

"The heterogeneity of cutaneous eruptions associated with nilotinib may imply its multiple effects on cutaneous metabolism," the authors write. "Checking vitamin C levels in a patient on a second-generation tyrosine kinase inhibitor may have clinical value, especially in those presenting with keratotic follicular papules with an erythematous rim."

Explore further

Case report describes scurvy in infant consuming almond milk

More information: Abstract
Full Text (subscription or payment may be required)

Copyright © 2016 HealthDay. All rights reserved.

Citation: Nilotinib associated with case of scurvy (2016, May 11) retrieved 30 July 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments